SETD7 and prostate carcinoma: SETD7 with frameshift mutation in castration-resistant prostate cancer [15] is the downstream target of miR-153; overexpression of miR-153 also promotes degradation of SETD7 and then suppresses ovarian cancer cell proliferation and invasion[16].